Literature DB >> 9128303

Normalization of esophageal pH with high-dose proton pump inhibitor therapy does not result in regression of Barrett's esophagus.

P Sharma1, R E Sampliner, E Camargo.   

Abstract

OBJECTIVE: The importance of esophageal acid control in the management of Barrett's esophagus is controversial. The objective of this study was to assess the impact of esophageal acid control on the symptoms of reflux disease, healing of erosive esophagitis, change in length of Barrett's epithelium, and the appearance of squamous islands.
METHODS: Thirteen of 27 patients on 60 mg lansoprazole underwent ambulatory 24 h esophageal pH monitoring while on therapy. Symptoms were recorded, and the length of Barrett's epithelium was measured, photographed, and biopsied every 6 months over an average of 5.7 yr.
RESULTS: Eight of 13 patients had a normal 24 h pH (group I, mean pH < 4, 0.8%), five patients had abnormal results (group II, mean pH < 4, 10.6%). Symptoms improved in all patients, and there was complete healing of erosive esophagitis in all patients. An increase in the number of squamous islands was noted in 62.5% of patients in group I and in 80% of patients in group II. The mean length of Barrett's epithelium at baseline and study completion in group I was 5.6 and 5.0 cm, respectively (mean decrease, 0.6 cm), and for group II was 4.2 and 4.2 cm, respectively (mean decrease, 0 cm). There was no significant difference in the change in length between the two groups (p = 0.494).
CONCLUSIONS: Although symptoms improved, erosive esophagitis healed, and squamous islands increased, there was no significant decrease in the length of Barrett's esophagus. Control of esophageal pH alone is not sufficient for the reversal of Barrett's esophagus.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9128303

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  33 in total

1.  Proton pump inhibitors for Barrett's oesophagus.

Authors:  G Triadafilopoulos
Journal:  Gut       Date:  2000-02       Impact factor: 23.059

2.  The pathogenesis of Barrett's esophagus: a process in continuum or discontinuum.

Authors:  R C Fitzgerald; M J Farthing
Journal:  Curr Gastroenterol Rep       Date:  2000-12

Review 3.  Update in internal medicine.

Authors:  F López-Jiménez; M Brito; Y W Aude; P Scheinberg; M Kaplan; D A Dixon; N Schneiderman; J F Trejo; L H López-Salazar; E J Ramírez-Barba; R Kalil; C Ortiz; J Goyos; A Buenaño; S Kottiech; G A Lamas
Journal:  Arch Med Res       Date:  2000 Jul-Aug       Impact factor: 2.235

Review 4.  Digestive system disorders: gastroesophageal reflux disease.

Authors:  D A Katzka
Journal:  West J Med       Date:  2000-07

5.  Combination of endoscopic argon plasma coagulation and antireflux surgery for treatment of Barrett's esophagus.

Authors:  H Tigges; K H Fuchs; J Maroske; M Fein; S M Freys; J Müller; A Thiede
Journal:  J Gastrointest Surg       Date:  2001 May-Jun       Impact factor: 3.452

6.  Long-term results of a randomized prospective study comparing medical and surgical treatment of Barrett's esophagus.

Authors:  Pascual Parrilla; Luisa F Martínez de Haro; Angeles Ortiz; Vicente Munitiz; Joaquín Molina; Juan Bermejo; Manuel Canteras
Journal:  Ann Surg       Date:  2003-03       Impact factor: 12.969

Review 7.  Current status of ablative therapies in esophageal disorders.

Authors:  P Sharma
Journal:  Curr Gastroenterol Rep       Date:  2001-06

Review 8.  Barrett's esophagus: environmental influences in the progression of dysplasia.

Authors:  Ralph A Boulton; Bernhard Usselmann; Imtiyaz Mohammed; Janusz Jankowski
Journal:  World J Surg       Date:  2003-07-28       Impact factor: 3.352

Review 9.  Potent gastric acid inhibition in the management of Barrett's oesophagus.

Authors:  Angel Lanas
Journal:  Drugs       Date:  2005       Impact factor: 9.546

10.  Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial.

Authors:  Elisabeth I Heath; Marcia Irene Canto; Steven Piantadosi; Elizabeth Montgomery; Wilfred M Weinstein; James G Herman; Andrew J Dannenberg; Vincent W Yang; Albert O Shar; Ernest Hawk; Arlene A Forastiere
Journal:  J Natl Cancer Inst       Date:  2007-04-04       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.